Skip to content
MarketScale
‹ Back to IndustriesHealthcare

TECHNOLOGY READINESS ASSESSMENTS AND MITIGATIONS

New product development efforts are a significant investment. Whether it is an established company that is acquiring new technology, or a startup with a new product concept hoping to move to commercialization; decisions should be made regarding what needs to be de-risked before moving to formal product development. Integrating technology readiness reviews into the product…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

New product development efforts are a significant investment. Whether it is an established company that is acquiring new technology, or a startup with a new product concept hoping to move to commercialization; decisions should be made regarding what needs to be de-risked before moving to formal product development.

Integrating technology readiness reviews into the product development process enables actionable processes that reduce project risk. This helps to avoid project delays, potential budgetary concerns, or the pressure to make design/feature compromises.

To determine whether a potential product has adequate technical maturity to effectively launch formal product development, the following steps should be considered:

  • Determine the stage of maturity of the current technology
  • Understand the implications of technology and project risks
  • Model, take measurements and analyze to decide whether core technology is capable of meeting the product requirements
  • Demonstrate that the device can provide adequate performance over the expected range of conditions
  • Determine whether the technology can scale to volume manufacturing and distribution

Evaluations begin with an objective review of each core technology critical to the operability of the device that may delay or prohibit market introduction.

This may involve proving whether core technology is adequate for use in a particular application. For example, does the new sensor being developed operate over the variety of conditions needed? Will environmental effects cause problems? Are measurements and control mechanisms adequate to provide safe and effective outcomes? Are there manufacturing difficulties in achieving the needed tolerances? These and other questions are explored, and appropriate efforts made, to bring the technology readiness level to the point that justifies moving the project to its subsequent phases.

Technology Readiness Assessment Tailored to Medical Devices

At Sunrise Labs, we implement a rigorous Technology Readiness Assessment customized specifically for medical devices. By analyzing the maturity of the technologies and the risk that each stage incurs, our assessment determines what challenges must be overcome in order for a device to be successfully engineered and commercialized.

We then improve the Technology Readiness through our feasibility Phase 0 process to prepare for a successful development effort.

To learn more about our process, check out our video on Technology Readiness.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512